Azithromycin ophthalmic - Laboratoires Thea

Drug Profile

Azithromycin ophthalmic - Laboratoires Thea

Alternative Names: Azydrop; Azyter; AzyterA; Bazyt; T-1225

Latest Information Update: 13 Aug 2015

Price : $50

At a glance

  • Originator Laboratoires Thea
  • Developer Laboratoires Thea; Spectrum Thea Pharmaceuticals
  • Class Antibacterials; Eye disorder therapies; Macrolides; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Infectious conjunctivitis
  • No development reported Bacterial infections; Blepharitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 13 Aug 2015 No recent reports on development identified - Phase-II for Bacterial infections (Prevention) in France and Spain (Ophthalmic)
  • 12 Aug 2015 No recent reports on development identified - Phase-II for Blepharitis in France (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top